Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $84.43 USD
Change Today +0.47 / 0.56%
Volume 664.3K
CLVS On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

clovis oncology inc (CLVS) Snapshot

Open
$83.85
Previous Close
$83.96
Day High
$86.48
Day Low
$82.42
52 Week High
05/14/15 - $102.28
52 Week Low
08/4/14 - $35.33
Market Cap
3.2B
Average Volume 10 Days
554.2K
EPS TTM
$-5.67
Shares Outstanding
37.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CLOVIS ONCOLOGY INC (CLVS)

clovis oncology inc (CLVS) Related Businessweek News

No Related Businessweek News Found

clovis oncology inc (CLVS) Details

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements with Advenchen Laboratories LLC, Avila Therapeutics, Inc., and Pfizer Inc.; collaboration and license agreement with Les Laboratoires Servier; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaboration with Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

136 Employees
Last Reported Date: 02/27/15

clovis oncology inc (CLVS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $901.7K
Co-Founder, Chief Medical Officer and Executi...
Total Annual Compensation: $643.9K
Co-Founder, Chief Regulatory Officer and Exec...
Total Annual Compensation: $575.2K
Co-Founder, Chief Financial Officer, Executiv...
Total Annual Compensation: $575.2K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $473.4K
Compensation as of Fiscal Year 2014.

clovis oncology inc (CLVS) Key Developments

Clovis Oncology Offering Of Common Stock; Mulls Acquisitions

Clovis Oncology, Inc. (NasdaqGS:CLVS) has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $275 million. Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, funding of its development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital.

Clovis Oncology Initiates Rolling NDA Submission to the FDA for Rociletinib in the Treatment of Advanced EGFR-Mutant Non-small Cell Lung Cancer

Clovis Oncology, Inc. announced that it has commenced the submission of a New Drug Application (NDA) regulatory filing to the U.S. Food and Drug Administration (FDA) for rociletinib for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation as detected by an FDA approved test. Rociletinib is the Company’s novel, oral targeted covalent (irreversible) mutant-selective inhibitor of EGFR in development for the treatment of NSCLC in patients with initial activating EGFR mutations, as well as the dominant resistance mutation T790M. Rociletinib was granted Breakthrough Therapy designation by the FDA in May 2014. Clovis agreed with FDA that the submission would be a rolling NDA and has filed the first component for potential accelerated approval of rociletinib in the U.S. The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the FDA on an ongoing basis. The Company intends to complete the NDA submission by late July 2015.

Clovis Oncology, Inc. Appoints Lindsey Rolfe as Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance, Effective Early August 2015

Clovis Oncology, Inc. announced that Dr. Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, has been named Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance, to become effective in early August 2015. Dr. Rolfe succeeds Dr. Andrew Allen, who will be stepping down from his role at Clovis at that time to create a new immuno-oncology focused biotechnology company and serve as its Chief Executive Officer. Dr. Rolfe joined Clovis in early 2010 and oversees rociletinib and rucaparib development in her current role as Senior Vice President of Clinical Development. Prior to her appointment as Executive VP and Chief Medical Officer, Dr. Rolfe served as Senior Vice President of Clinical Development at Clovis. Dr. Rolfe previously served in senior oncology development roles at Celgene Corporation, Pharmion Corporation, Cambridge Antibody Technology, UCB Inc. and Celltech Group plc. As Chief Medical Officer at Clovis, Dr. Rolfe will be responsible for clinical development, preclinical development, clinical operations and pharmacovigilance and will also serve on the Company’s executive committee. She will be based in the Company’s San Francisco office.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLVS:US $84.43 USD +0.47

CLVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLVS.
View Industry Companies
 

Industry Analysis

CLVS

Industry Average

Valuation CLVS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLOVIS ONCOLOGY INC, please visit www.clovisoncology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.